{"id":"W3020771563","doi":"10.1056/nejmoa1911440","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2237,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; Janssen Biotech; Foundation Medicine; Pharmacyclics; Genentech; Astellas Pharma Europe; Tulane University; Eisai; Astellas Pharma; Merck Sharp and Dohme; Radboud Universitair Medisch Centrum; EMD Serono; Radboud Universiteit; AstraZeneca; Invitae; Massachusetts Medical Society; Bayer HealthCare; Sanofi; Exelixis; Pfizer; Northwestern University; Ipsen; Clovis Oncology; F. Hoffmann-La Roche; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Poly ADP ribose polymerase; Prostate cancer; Homologous recombination; PARP inhibitor; DNA repair; Cancer research; Polymerase; DNA Damage Repair; Medicine; Prostate; Gene; Oncology; Cancer; Biology; Internal medicine; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08227651790290585,"score_gpt":0.3739222685155358,"score_spread":0.2916457506126299,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}